Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIANGLE trial in generalized mantle cell lymphoma
2014-001363-12Phase 3Active
- Sponsor
- LMU Klinikum
- Start
- Oct 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ibrutinib, rituximab, cytarabine, cyclophosphamide, doxorubicin and 4 more in mantle cell lymphoma (MCL) (3 arms), sponsored by LMU Klinikum. Primary endpoint: Failure-free survival. Started Oct 2015; status: active.
02
Drugs
ibrutinibrituximabcytarabinecyclophosphamidedoxorubicin
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2014-001363-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001363-12.